medigraphic.com

2011, Número 3

<< Anterior

Rev Cuba Endoc 2011; 22 (3)


Bases genéticas del síndrome de ovarios poliquísticos

Ovies CG, Martínez de SA, Monteagudo PG, Sardiñas DI

Idioma: Español
Referencias bibliográficas: 58
Paginas: 255-265
Archivo PDF: 65.40 Kb.


RESUMEN

El síndrome de ovarios poliquísticos es el trastorno endocrino que más afecta la esfera reproductiva de la mujer en la edad fértil, sus causas se desconocen con exactitud, pero la mayoría de los expertos coinciden en plantear que es una entidad multifactorial, en la que los factores genéticos cada vez cobran mayor importancia. En los últimos años se han identificado varios genes involucrados en los procesos patogénicos de este síndrome, y dentro de estos, los más importantes son aquellos que codifican para enzimas de la esteroidogénesis, para el receptor de insulina y otras hormonas relacionadas con la acción de la insulina, así como las gonadotropinas y sus receptores, aspectos sobre los cuales trata la siguiente revisión.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Stein I, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol. 1935;29:181-91.

  2. Smith KD, Se PW. Polycystic ovarian disease (PCO). A report of 301 cases. Am J Obstet Gynecol. 1965;93:994-1 001.

  3. American College of Obstetricians and Gynecologists A. Practice Bulletin 41 on polycystic ovary syndrome can be found at Obstet Gynecol. 1990;100:1 389-91.

  4. ESHRE/ASRM-Sponsored Pcwg. Consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) 2004 Rotterdam. Hum Reprod. 2004:41-7.

  5. Ovies CG, Verdeja VOL, Zamora RH. Frecuencia y características clínicas, hormonales y ultrasonográficas sugestivas de síndrome de ovarios poliquísticos en un grupo de mujeres con síndrome metabólico. Rev Cubana Endocrinol. 2008;19:20-4.

  6. Acosta C. Patrón hormonal de mujeres con diagnóstico clínico y ecográfico del síndrome de ovarios poliquísticos. Rev Cubana Endocrinol. 2004;15:13-7.

  7. Jerome FS, III. Some New Thoughts on the Pathophysiology and Genetics of Polycystic Ovary Syndrome. Annals of the New York Academy of Sciences. 2003;997 (Women's Health and Disease: Gynecologic and Reproductive Issues):42-8.

  8. Cooper HE, Spellacy WN, Prem KA, Cohen WD. Hereditary factors in the Stein Leventhal syndrome. Am J Obstet Gynecol. 1968;100:371-87.

  9. Givens JR. Ovarian hyperthecosis. N Engl J Med. 1971;285:691-4.

  10. Wilroy RS Jr, Givens JR, Wiser WL, Coleman SA, Andersen RN, Summitt RL. Hyperthecosis: an inheritable form of polycystic ovarian disease. Birth Defects Orig Artic. 1975;11:81-5.

  11. Ferriman D, Purdie AW. The inheritance of polycystic ovarian disease and a possible relationship to premature balding. Clin Endocrinol. 1979;11:291-300.

  12. Govind A OM, Clayton RN. Policystic Ovaries are Inherited as an Autosomal Dominant Trait: Analysis of 29 Polycystic Ovary Syndrome and 10 Control Families. J Clin Endocrinol Metab. 1999;84:38-43.

  13. Hague WM, Adams J, Reeders ST, Peto TE, Jacobs HS. Familial polycystic ovaries: a genetic disease? Clin Endocrinol (Oxf). 1988;29:593-605.

  14. Lunde O, Magnus P, Sandvik L, Hoglo S. Familial clustering in the polycystic ovarian syndrome. Gynecol Obstet Invest. 1989;28:23-30.

  15. Norman RJ, Masters S, Hague W. Hyperinsulinemia is common in family members of women with polycystic ovary syndrome. Fertil Steril. 1996;66:942-7.

  16. Legro RS, Driscoll D, Strauss JF 3rd, Fox J, Dunaif A. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Nat Acad Sci USA. 1998;95:14 956-60.

  17. Diamanti-Kandarakis E, Alexandraki K, Bergiele A, Kandarakis H, Mastorakos G, Aessopos A. Presence of metabolic risk factors in non-obese PCOS sisters: evidence of heritability of insulin resistance. J Endocrinol Invest. 2004;27:931-6.

  18. Kahsar-Miller MD, Nixon C, Boots LR. Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil Steril. 2001;75:53-8.

  19. Urbanek M, Legro RS, Driscoll DA. Thirty seven genes for polycystic ovary syndrome: strongest evidence for linkage in folistain. Proc Nati Acad Sci USA. 1999;96:8 573-5.

  20. Qin KN, Rosenfield RL. Role of cytochrome P450c 17 in polycystic ovary syndrome. Mol Cell Endocrinol. 1998;145:111-21.

  21. Wood JR,Ho CK, Nelson-Degrave VL, McAllster JM, Strauss JF 3rd. The molecular signature of polycystic ovary syndrome (PCOS) theca cells defined by gene expression profiling. J Reprod Immunol. 2004;63:51-60.

  22. Nelson VL, Legro RS, Strauss JF. Augmwnted androgens production is stable steroidogenic phenotype of propaged theca cells from polycytic ovaries. Mol Endo. 1999;13:6 946-57.

  23. Gharani N, Waterworth DM, Batty S. association of the steroid synthesis gene CYP 11 α with polycytsic ovary syndrome and hyperandrogenism. Hum Mol Gen. 1997;6:397-402.

  24. Frank S, Batty S, White D, Williamson R, Mccarthy M. The genect basic of polycystic ovary syndrome. Hum Reprod. 1997;2:2 641-8.

  25. Pugeat M. Genetics of the polycystic ovary syndrome and Therapeautic perpectives. Rev Med Chir Soc Med Nat. 2000;104:11-9.

  26. Jakubowki L. Genetic aspects of polycystic ovary syndrome. Endokrynol Pol. 2005;56:285-93.

  27. Carey AH, Waterworth D, Patel K. Polycustic ovaries and premature male pattern baldness are associated with one allele of the steroid matabolism gene CYP17. Hum Mol Gen. 1994;3:1 873-6.

  28. Pérez MS, Cerrone GE, Benencia H, Marquez N, De Piano E, Frechtel G. Polimorfismos en los genes CYP11 α y CYP17 y etiología del hiperandrogenismo en pacientes con poliquistosis ovárica. Medicina. 2008;68:129-34.

  29. Tapanainen JS, Koivunen R, Fauser BC, Taylor AE, Clayton RN, Rajkowa M, et al. A new contributing factor to polycystic ovary syndrome: the genetic variant of luteinizing hormone. J Clin Endocrinol Metab. 1999;84:1 711-5.

  30. Lamminen T, Hubtaniemi I. A common genetic variant of luteinizing hormone; relation to normal and aberrant pituitary-gonadal function. Eur J Pharmacol. 2001;23(414):17.

  31. Unsal T, Konac E, Yesilkaya E, Yilmaz A, Bideci A, Ilke H, et al. Genetic polymorphismsof FSHR, CYP17, CYP1A!,CAPN10, INSR, SERPINE1 genes in adolescent girls with polycystic ovary syndrome. J Assist Reprod Genet. 2009;26:205-16.

  32. Mukherjee S, Maitra A. Molecular & genetic factors contributing to insulin resistence in polycystic ovary syndrome. Indian J Med Res. 2010;131:743-60.

  33. Jin L, Huang HF, Jin F, Qian YL. Polymorphism in insulin receptor gene exon 17 in women with polycystic ovary syndrome. Zhonghua Fu Chan Ke ZaZhi. 2005;40:323- 6.

  34. Siegel S, Futterweit W, Davies TF, Concepcion ES, Greenberg DA, Villanueva R, et al. A C/T single nucleotide polymorphism at the tyrosine kinase domain of the insulin receptor gene is associated with polycystic ovary syndrome. Fertil Steril. 2002;78:1 240-3.

  35. Chen ZJ, Shi YH, Zhao YR, Li y, Tang R, Zhao LX. Correlation between single nucleotide polymorfism of insulin receptor gene with polycystic ovary syndrome. Zhonghua Fu Chan Ke Za Zhi. 2004;39:582-5.

  36. Jin L, Zhu XM, Luo Q, Qian y, Jin F, Huang HF. A novel SNP at exon 17 of INSR associated with decreased insulin sensitivity in chinese women with PCOS. Mol Hum Reprod. 2006;12:151-5.

  37. Mukherjee S, Shaikh N, Khavale S, Shinde G, Meherji P, Shah N. Genetic variation in exon 17 of INSR is associated with insulin resistence and hyperandrogenemia among lean Indian womwn with polycystic ovary syndrome. Eur J Endocrinol. 2009;160:855-62.

  38. Villuendas G, Botella-Carretero JI, Roldan B, Sancho J. Escobar-Morreale HF, San Millan JL. Polymorphisms in the insulin receptor substrate-1 (IRS-1) gene and the insulin receptor substrate-2 (IRS-2) gene influence glucose homeostasis and body mass index in women with polycystic ovary syndrome and non-hyperandrogenic controls. Hum Reprod. 2005;20:3 184-91.

  39. Dilek S, Ertunc D, Tok EC, Erdal EM, Aktas A. Association of Gly972Arg variant of insulin receptor substrate-1 with metabolic features in women with polycystic ovary syndrome. Fertil Steril. 2005;84:407-12.

  40. Valdés P, Cerda A, Barrenechea C, Kehr M, Soto C, Salazar 93. LA. No association between common Gly972Arg variant of the insulin receptor substrate-1 and polycystic ovary syndrome in Southern Chilean women. Clin Chim Acta. 2008;390:63-6.

  41. Escobar-Morreale HF, Luque-Ramírez M, San Millán JL. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev. 2005;26:251-82.

  42. Ehrmann DA, Schwarz PE, Hara M, Tang X, Horikawa Y. Imperial J. Relationship of calpain-10 genotype to phenotypic features of polycystic ovary syndrome. J Clin Endocrinol Metab. 2002;87:1 669-73.

  43. Gonzalez A, Abril E, Roca A, Aragon MJ, Figueroa MJ,. Velarde P. Specific CAPN10 gene haplotypes influence the clinical profile of polycystic ovary patients. J Clin Endocrinol Metab. 2003;88:5 529-36.

  44. Yilmaz M, Yurtcu E, Demirci H, Ergun MA, Ersoy R, Karakoc A, et al. Calpain 10 gene single-nucleotide 44 polymorphism may have an influence on clinical and metabolic features in patients with polycystic ovary syndrome. J Endocrinol Invest. 2009;32:13-7.

  45. Escobar-Morreale HF, Peral B, Villuendas G, Calvo RM. Sancho J, San Millan JL. Common single nucleotide polymorphisms in intron 3 of the calpain-10 gene influence hirsutism. Fertil Steril. 2002;77:581-7.

  46. Vollmert C, Hahn S, Lamina C, Huth C, Kolz M, Schöpfer. Wendels A. Calpain-10 variants and haplotypes are associated with polycystic ovary syndrome in Caucasians. Am J Physiol Endocrinol Metab. 2007;292:836-44.

  47. Orio F Jr, Matarese G, Di Biase S, Palomba S, Labella D, Sanna V. Exon 6 and 2 peroxisome proliferator-activated receptor-gamma polymorphisms in polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:5 887-92.

  48. Gu BH, Baek KH. Pro12Ala and His447His polymorphisms of PPAR-gamma are associated with polycystic ovary syndrome. Reprod Biomed. 2009;18:644-50.

  49. Baba T, Endo T, Sata F, Nagasawa K, Honnma H, Kitajima Y, et al. The contributions of resistin and adiponectin gene single nucleotide polymorphisms to the genetic risk for polycystic ovary syndrome in a Japanese population. Gynecol Endocrinol. 2009;25:498-503.

  50. Zhang N, Shi YH, Hao C, Gu HF, Li Y, Zhao Y. Association of C45G15G(T/G) and C276(G/T) polymorphisms in the ADIPOQ gene with polycystic ovary syndrome among Han Chinese women. Eur J Endocrinol. 2008;158:255-60.

  51. Escobar-Morreale HF, Villuendas G, Botella-Carretero JI, Álvarez-Blasco F, Sanchón R, Luque-Ramírez M. Adiponectin and resistin in PCOS: a clinical, biochemical and molecular genetic study. Hum Reprod. 2006;21:2 257-65.

  52. Urbanek M, Du Y, Silander K, Collins FS, Steppan CM, Strauss JF. Variation in resistin gene promoter not associated with polycystic ovary syndrome. Diabetes. 2003;52:214-7.

  53. Xita N, Georgiou I, Tsatsoulis A, Kourtis A, Kukuvitis A, Panidis D. A polymorphism in the resistin gene promoter is associated with body mass index in women with polycystic ovary syndrome. Fertil Steril. 2004;82:1 466-7.

  54. Oksanen L, Tiitinen A, Kaprio J, Koistinen HA, Karonen SL, Kontula K. No evidence for mutations of the leptin or leptin receptor genes in women with polycystic ovary syndrome. Mol Hum Reprod. 2000;6:873-6.

  55. Erel CT, Cine N, Elter K, Kaleli S. Leptin receptor variant in 122 women with polycystic ovary syndrome. Fertil Steril. 2002;78:1 334-5.

  56. Xita N, Tsatsoulis A, Chatzikyriakidou A , Georgiou I. Association of the (TAAAA)n repeat polymorphism in the sex hormone-binding globulin (SHBG) gene with polycystic ovary syndrome and relation to SHBG serum levels. J Clin Endocrinol Metab. 2003;88:5 976-80.

  57. Diamanti-Kandarakis E, Palioniko G, Alexandraki K, Bergiele A, Koutsouba T, Bartzis M. The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) levels. Eur J Endocrinol. 2004;150:793-8.

  58. Mllinar B, Ferk P, Pfeifer M, Gersak K, Marc J. Lipin 1 Gene Polymorphisms in Polycystic Ovary Syndrome. Horm Metab Res. 2011;29 (Epub ahead of print).




2020     |     www.medigraphic.com